Eli Lilly, Insitro ink a new kind of AI drug development deal
Oct. 9, 2024
Health Tech Reporter
Machine-learning drug development company Insitro has inked three agreements with Eli Lilly for new medicines for metabolic diseases. But the deal is a little different compared to many recent deals between burgeoning artificial intelligence upstarts and established pharma giants: After identifying drug candidates, Insitro will be responsible for commercializing the drugs, and Lilly will be eligible for milestones and royalties.
Even though the company has never brought drugs into the clinic before, Insitro is betting on itself. Since the company’s technology platform extends to clinical trial insights, CEO Daphne Koller thinks it will give Insitro the edge over another company performing their clinical trials. But the move is a selfish one, too.
advertisement
“We’re a data company,” she told STAT in an interview. “AI is only as good as the data that you feed it, and data from your own patients is probably the most precious commodity out there. And so we wanted to be able to have that.”
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.
Already have an account? Log in
Monthly
$39
Totals $468 per year
$39/month Get StartedTotals $468 per year
Starter
$20
for 3 months, then $399/year
$20 for 3 months Get StartedThen $399/year
Annual
$399
Save 15%
$399/year Get StartedSave 15%
11+ Users
Custom
Savings start at 25%!
Request A Quote Request A QuoteSavings start at 25%!
2-10 Users
$300
Annually per user
$300/year Get Started$300 Annually per user
View All Plans
To read the rest of this story subscribe to STAT+.
Subscribe Log In Artificial intelligence, drug development, Eli Lilly, STAT+ Submit a correction requestReprints
Newsletter
Tech is transforming health care and life sciences. Our original reporting is here to keep you ahead of the curve.
